Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Other Accumulated Expenses (2021 - 2025)

Roivant Sciences' Other Accumulated Expenses history spans 5 years, with the latest figure at $10.2 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 80.84% year-over-year to $10.2 million; the TTM value through Dec 2025 reached $10.2 million, down 80.84%, while the annual FY2025 figure was $1.6 million, 95.8% down from the prior year.
  • Other Accumulated Expenses reached $10.2 million in Q4 2025 per ROIV's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $72.6 million in Q3 2023 to a low of $1.5 million in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $26.6 million, with a median of $14.7 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: surged 1940.32% in 2022, then tumbled 95.8% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $12.4 million in 2021, then increased by 15.08% to $14.3 million in 2022, then skyrocketed by 204.87% to $43.6 million in 2023, then grew by 22.55% to $53.5 million in 2024, then tumbled by 80.84% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Other Accumulated Expenses are $10.2 million (Q4 2025), $1.5 million (Q3 2025), and $49.8 million (Q2 2025).